

(A unit of Sandhya Pharma and Research Unit) (BF-45, Shalimar Bagh,Delhi-110088)

Quality Operating Process	Document No: SNP/001				
Adverse Drug Reaction Event	Date of Issue :01/Oct/2020 Issue No. : SNP/I/001 Date of Revision: 01/Oct/2021 Revision No. :				

Service Name :	Adverse drug reaction event
Date Created :	01/Oct/2020
Approved By :	Dr. Vikas Gupta
Reviewed By :	Sandhya Gupta





(A unit of Sandhya Pharma and Research Unit) (BF-45, Shalimar Bagh,Delhi-110088)

Quality Operating Process	Document No: SNP/001					
Adverse Drug Reaction	Date of Issue :01/Oct/2020					
Event	Issue No. : SNP/I/001					
	Date of Revision: 01/Oct/2021					
	Revision No. :					

AMENDMENT SHEET

No.	Section and Page	Date	Amendment	Signature



(A unit of Sandhya Pharma and Research Unit)
(BF-45, Shalimar Bagh, Delhi-110088)

Quality Operating Process	Document No: SNP/001					
Adverse Drug Reaction Event	Date of Issue :01/Oct/2020 Issue No. : SNP/I/001 Date of Revision: 01/Oct/2021 Revision No. :					

A. Purpose:

To provide guideline instruction for monitoring adverse drug reaction event and ensure its proper reporting.

B. Scope:

Clinic wide

C. Protocol:

In case of any drug reaction / adverse reaction actions taken are as follows:

- 1. The person noticing the reaction i.e. Doctor / Patient immediately informs the concerned doctor and clinical management is initiated then & there.
- 2. The Doctor informs in charge pharmacy & Main Medicine store.
- 3. The ADR [Adverse drug reaction] form is filled up by the concerned doctor
- 4. Drug responsible for adverse reaction is identified.
- 5. Batch of the drug identified.
- 6. All Patient rooms & areas where the drug has been issued are advised NOT to use the drug of that particular batch.
- 7. Information regarding any such similar reactions anywhere in the Clinic is gathered and documented and forwarded to the Medical Superintendent.
- 8. All such events are monitored and evaluated and appropriate action taken depending on the nature of the adverse reaction
- 9. Such action may take the form of observation or in extreme cases withdrawal of the drug throughout the hospital.
- 10. Drug causing adverse reaction is closely monitored and analyzed by drug and therapeutic committee

1. Drug Recall Procedure

- 1. Once the drug causing adverse reaction is identified, particular batch of the drug is immediately withdrawn by pharmacy, wherever issued within the hospital.
- 2. Company & distributor are immediately informed regarding the adverse reaction and called to find out the reasons & actions to be taken.
- 3. Total medicine of that particular batch is returned to supplier.
- 4. Report is presented before Quality management committee and further action is taken.



(A unit of Sandhya Pharma and Research Unit) (BF-45, Shalimar Bagh,Delhi-110088)

Quality Operating Process	Document No: SNP/001
Adverse Drug Reaction	Date of Issue :01/Oct/2020
Event	Issue No. : SNP/I/001
	Date of Revision: 01/Oct/2021
	Revision No. :

SUSPECTED ADVERSE DRUG REACTION REPORTING FORM

						For VOLUNTARY reporting of Adverse Drug Reactions by health care professionals								
												To ce	be filled ntres rece	in by Pharmacovigillance siving the form.
Α	. Patie	nt infor	mation					12.	Relevant	tests/ labo	ratory (data, ir	ncluding d	ates
1. F	atient id	lentifier in	ev		5.000	ом с	_							
	In co	onfidence	Dat Birt	e of h:	4. Wei	ght	Kgs							
			dverse R					\vdash						
			arted (dd/mr	n/yy):				 Other relevant history, including pre-existing medical conditions (e.g., allergies, race, pregnancy, smoking alcohol use, hepatic/ renal dysfunction, etc.) 						
6. D	ate of re	ecovery (dd/mm/yy):											
7. Describe reaction or problem														
							- 1	14. 5	Seriousne	ess of the r	reaction	n		
										l/mm/yy)				genital anomaly
									ife threat					uired intervention
									nospitaliz or prolong	ation-initia	1			revent permanent airment/ damage
									Disability	,				er (specify)
								15.0	Outcomes	9				
								□ Fatal □ Recovering □ Unknown □ Continuing □ Recovered □ Other (specify)						
С	. Susp	ected r	nedicatio	n(s)				_						
SI.		e (brand	Manufac-	Batch No.	Exp. Date	Dose	Route	. _		Therapy				Reason for Use
No.	and / o	r generic me)	turer (If known)	/ Lot No. (If known)	(If known)	used	used	Troquency -				or prescribed for		
_		,		(II KIIOWII)				+		Date sta	inted	Date	stopped	presented for
i								┸						
ii								┸						
iii														
iv														
	I. No. per C				opped or dos					ction reapp				
_^s	i	Yes	No	Unknow	n NA	Red	uced do	se	Yes	No	Unkn	own	NA	If reintroduced, dose
	ii													
	iii													
<u> </u>	iv												-114	
11. Concomitant medical products and therapy dates including self medication and herbal remedies (exclude those used to treat							D. Reporter (see confidentiality section in first page) 16. Name and Professional Address;							
reaction)							"	TV. Harris and Filotessional Address.						
							1	Pin code	·-		E	mail:		
						1			with ST	D Cod	le:			
									Speciality			_	Signatu	
						17. Occupation 18. Date of this report				of this report				
												- 1		

